Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
Biogen (BIIB) and Neomorph have announced a research collaboration to develop molecular glue degraders for Alzheimer's, rare neurological, and immunological diseases. The partnership combines Neomorph's molecular glue discovery platform with Biogen's expertise in disease research and drug development. Under the agreement, Neomorph will receive an upfront payment and is eligible for milestone payments totaling up to $1.45 billion, plus potential royalties ranging from mid-single digit to low double-digit percentages. The collaboration aims to identify and validate small molecule therapeutic molecular glue degraders for high-priority targets, with Biogen leading the clinical development and commercialization efforts.
Biogen (BIIB) e Neomorph hanno annunciato una collaborazione nella ricerca per sviluppare degradatori a base di molecole adesive per l'Alzheimer, malattie neurologiche rare e malattie immunologiche. La partnership combina la piattaforma di scoperta delle molecole adesive di Neomorph con l'esperienza di Biogen nella ricerca sulle malattie e nello sviluppo di farmaci. In base all'accordo, Neomorph riceverà un pagamento iniziale e sarà idonea per pagamenti legati a traguardi che possono arrivare fino a 1,45 miliardi di dollari, oltre a potenziali diritti royalty che variano da percentuali a una cifra media a percentuali a bassa doppia cifra. La collaborazione si propone di identificare e convalidare degradatori terapeutici a base di piccole molecole adesive per obiettivi di alta priorità, con Biogen che guiderà gli sforzi di sviluppo clinico e commercializzazione.
Biogen (BIIB) y Neomorph han anunciado una colaboración en investigación para desarrollar degradadores de moléculas adhesivas para la enfermedad de Alzheimer, enfermedades neurológicas raras y enfermedades inmunológicas. La asociación combina la plataforma de descubrimiento de moléculas adhesivas de Neomorph con la experiencia de Biogen en investigación de enfermedades y desarrollo de medicamentos. Según el acuerdo, Neomorph recibirá un pago inicial y será elegible para pagos por hitos que totalizan hasta 1.45 mil millones de dólares, además de posibles regalías que van desde un porcentaje de un solo dígito medio hasta porcentajes de doble dígito bajo. La colaboración tiene como objetivo identificar y validar degradadores terapéuticos de moléculas adhesivas de pequeñas moléculas para objetivos de alta prioridad, con Biogen liderando los esfuerzos de desarrollo clínico y comercialización.
Biogen (BIIB)과 Neomorph는 알츠하이머, 희귀 신경질환 및 면역 질환을 위한 분자 글루 분해제를 개발하기 위한 연구 협력 관계를 발표했습니다. 이 파트너십은 Neomorph의 분자 글루 발견 플랫폼과 Biogen의 질병 연구 및 약물 개발 전문 지식을 결합합니다. 계약에 따라 Neomorph는 초기 지급금을 받게 되며 최대 14억 5천만 달러에 달하는 마일스톤 지급금을 받을 자격이 있습니다. 또한 중간 단일 자리에서 낮은 두 자리 수의 비율에 해당하는 잠재적 로열티도 포함됩니다. 이 협력의 목표는 높은 우선 순위 타겟에 대한 작은 분자 치료용 분자 글루 분해제를 식별하고 검증하는 것이며, Biogen이 임상 개발 및 상용화를 주도할 것입니다.
Biogen (BIIB) et Neomorph ont annoncé une collaboration de recherche pour développer des dégradateurs de colle moléculaire pour la maladie d'Alzheimer, les maladies neurologiques rares et les maladies immunologiques. Ce partenariat combine la plateforme de découverte de colle moléculaire de Neomorph avec l'expertise de Biogen en matière de recherche sur les maladies et de développement de médicaments. En vertu de l'accord, Neomorph recevra un paiement initial et pourra bénéficier de paiements d'étape pouvant atteindre jusqu'à 1,45 milliard de dollars, ainsi que de redevances potentielles allant de pourcentages à un chiffre moyen à des pourcentages à faible double chiffre. La collaboration vise à identifier et valider des dégradateurs thérapeutiques de colle moléculaire à petites molécules pour des cibles de haute priorité, Biogen dirigeant les efforts de développement clinique et de commercialisation.
Biogen (BIIB) und Neomorph haben eine Forschungskooperation zur Entwicklung von molekularen Kleberabbauern für Alzheimer, seltene neurologische und immunologische Erkrankungen bekannt gegeben. Die Partnerschaft kombiniert die Entdeckungsplattform für molekulare Kleber von Neomorph mit Biogens Expertise in der Krankheitsforschung und der Arzneimittelentwicklung. Im Rahmen des Vertrags erhält Neomorph eine Vorauszahlung und ist berechtigt, Meilensteinzahlungen von insgesamt bis zu 1,45 Milliarden Dollar zu erhalten, zuzüglich potenzieller Lizenzgebühren, die von mittleren einstelligen bis zu niedrigen zweistelligen Prozentsätzen reichen. Die Zusammenarbeit zielt darauf ab, therapeutische molekulare Kleberabbauer für hochpriorisierte Ziele zu identifizieren und zu validieren, wobei Biogen die klinische Entwicklung und die Vermarktungsbemühungen leitet.
- Total potential deal value of up to $1.45B including milestone payments
- Access to Neomorph's proprietary molecular glue discovery platform
- Expansion into new therapeutic approach for difficult-to-treat targets
- Significant milestone payments and royalties payable to Neomorph
- Research and development costs reimbursement required
Insights
This strategic collaboration marks a significant advancement in Biogen's protein degradation capabilities. The deal structure, with
Molecular glue degraders represent a cutting-edge approach to drug development, potentially offering solutions for previously "undruggable" targets. The technology could be particularly valuable for Biogen's core focus areas, especially in Alzheimer's disease where traditional approaches have had success. The collaboration's emphasis on multiple targets across different therapeutic areas provides important pipeline diversification.
The financial terms, including mid-single to low double-digit royalties, align with industry standards for early-stage platform technology deals. The milestone-heavy structure helps preserve Biogen's current cash position while incentivizing successful development.
- The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen.
- Collaboration leverages Neomorph's leading molecular glue discovery platform and Biogen’s deep expertise in Alzheimer’s, rare, and immunological diseases.
CAMBRIDGE, Mass. and SAN DIEGO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases.
As part of the collaboration, the companies aim to utilize Neomorph's proprietary molecular glue discovery platform to accelerate the identification and validation of novel small molecule therapeutic molecular glue degraders. Small molecule protein degraders have been shown to effectively drug challenging targets with differentiated pharmacology from more traditional inhibitors. Pursuing innovative solutions aimed at modulating protein levels through targeted degradation holds promise for treating complex neurological, immunological and rare diseases. This collaboration will leverage Neomorph’s research strengths in targeted protein degradation and Biogen’s deep scientific expertise and drug development capabilities.
"As part of our modality agnostic research strategy, Biogen is committed to investing in new approaches to unlock biological targets that have remained difficult to reach," said Jane Grogan, Ph.D., Head of Research at Biogen. "This collaboration with Neomorph reflects the approach we want to take to pair our internal drug development expertise with cutting-edge external innovation to create clinically meaningful therapies for patients."
"Neomorph's molecular glue degrader platform represents a unique approach to drug discovery," said Phil Chamberlain, DPhil, Co-Founder, President, and Chief Executive Officer of Neomorph. "We are excited to partner with Biogen, a leader in Alzheimer’s, rare, and immunological diseases, to explore the potential of our technology in addressing some of the most challenging and valuable targets in these fields."
Under the terms of the agreement, Biogen and Neomorph will collaborate to identify, validate, and optimize small molecule molecular glue degraders for several high-priority targets and Biogen will advance clinical candidates for further development and potential commercialization. Neomorph will receive an upfront payment and is eligible to receive contingent milestone payments per target as the collaboration progresses through various stages. These include certain pre-clinical milestones payable in the near-term and certain clinical, regulatory, commercial and sales milestones that are anticipated to occur later this decade and beyond, for a total consideration of up to
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.
About Neomorph
Neomorph is a biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ‘undruggable’ targets. Neomorph was founded in 2020 and is venture-backed by Deerfield Management Company.
Neomorph’s team is comprised of industry-leading experts in protein degradation and molecular glues who have a track record of groundbreaking discoveries in the field. The team at Neomorph is committed to leadership in advancing the science and technology of molecular glue drug discovery while prosecuting a pipeline of projects through clinical development.
Neomorph is headquartered in San Diego, California. For more information, visit www.neomorph.com and follow us on LinkedIn.
Biogen Safe Harbor
This press release contains forward-looking statements, including statements relating to our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; the potential for molecular glue degraders; regulatory discussions, submissions, filings, and approvals; and the potential benefits, safety, and efficacy of our and our collaboration with Neomorph. These forward-looking statements may be accompanied by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "potential," "possible," "prospect," "will," "would," and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later-stage or larger-scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including our dependence on sales from our products; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; failure to compete effectively; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights; and the risks and uncertainties relating to intellectual property claims and challenges.
These statements speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.
| MEDIA CONTACT(S): Biogen Jack Cox + 1 781 464 3260 public.affairs@biogen.com Neomorph media@neomorph.com | INVESTOR CONTACT(S): Biogen Stephen Amato +1 781 464 2442 IR@biogen.com Neomorph inquiries@neomorph.com |
FAQ
What is the total value of the Biogen-Neomorph collaboration agreement?
What diseases will Biogen (BIIB) target through the Neomorph collaboration?
What royalty rates will Biogen (BIIB) pay to Neomorph?
What technology will be used in the Biogen (BIIB) and Neomorph collaboration?
